The global In-vitro Colorectal Cancer Screening Tests market size is expected to reach USD 1,954.77 Million by 2034, according to a new study by Polaris Market Research. The report “In-vitro Colorectal Cancer Screening Tests Market Size, Share, Trends, Industry Analysis Report: By Test (Fecal Occult Blood Tests, Biomarker Tests, and Other Methods), End Use, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The in-vitro colorectal cancer screening tests market encompasses diagnostic analyses performed on biological specimens, such as stool or blood, to identify the presence of colorectal cancer or its preliminary stages, including adenomatous polyps. These tests are fundamental in the proactive detection of the disease, enabling timely medical intervention and substantially enhancing patient prognosis. The market's significance is underscored by the increasing global incidence of colorectal cancer and the growing recognition of the benefits associated with early diagnosis through effective screening methodologies.
The in-vitro colorectal cancer screening tests market is experiencing growth driven by several key factors. A primary driver is the rising global prevalence of colorectal cancer, necessitating widespread screening efforts. Technological advancements have led to the development of more user-friendly and accurate non-invasive tests, such as stool-based DNA tests and emerging blood-based biomarkers, further fueling market expansion. Public health initiatives and governmental support for colorectal cancer screening programs also contribute significantly to increased adoption rates. The convenience and accessibility offered by certain in-vitro tests, including at-home collection options, are enhancing patient compliance and broadening the reach of screening efforts, thereby shaping the positive market outlook.
In-vitro Colorectal Cancer Screening Tests Market Report Highlights:
By test, the fecal occult blood tests segment currently holds the largest market share globally. This is primarily due to their long-established use in screening programs, relative affordability, and widespread integration into healthcare systems across various regions.
By end use, the hospitals and clinics segment currently accounts for the largest share of the market. This is attributed to their central role in patient care pathways, serving as primary points for screening test ordering and administration within established healthcare systems worldwide.
By region, North America currently holds the largest share of the in-vitro colorectal cancer screening tests market. The Asia Pacific region is emerging as a high-growth area, driven by increasing healthcare expenditure and a rising prevalence of colorectal cancer.
Key participants actively involved in the in-vitro colorectal cancer screening tests market include Exact Sciences Corporation, F. Hoffmann-La Roche AG, Abbott Laboratories, BioMerieux SA, QIAGEN N.V., Sysmex Corporation, Guardant Health, Inc., Epigenomics AG, and MDxHealth SA.
Polaris Market Research has segmented the In-vitro Colorectal Cancer Screening Tests market report based on test, end use, and region:
By Test Outlook (Revenue-USD Million, 2020–2034)
Fecal Occult Blood Tests
Biomarker Tests
Other Methods
By End Use Outlook (Revenue-USD Million, 2020–2034)
Hospitals
Clinics
Diagnostic Laboratories
Others
By Regional Outlook (Revenue-USD Million, 2020–2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia-Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia-Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook